Search results for

As the Gulf Cooperation Council’s patent system goes from strength to strength, Ralph Cunningham examines how patent owners are benefiting from improved protection and enforcement throughout the region

The fair basis requirement has vanished from UK patent law – but remains an important consideration in Australia. Barry Eagar says overseas applicants must pay attention to this requirement and ensure that the claims correspond to the patent specification

Artistic copyright has sometimes been seen as the Cinderella of copyright law. Simon Stokes argues that recent artistic copyright cases in Europe and North America are pushing copyright law to its limits. This has implications for the creative industries generally.

The directive concerning legal protection of biotechnological inventions (98/44/EC) has not been annulled according to a judgment made by the European Court of Justice (ECJ) on October 9 2001 (C 377/98).

As the Gulf Cooperation Council’s patent system goes from strength to strength, Ralph Cunningham examines how patent owners are benefiting from improved protection and enforcement throughout the region

Artistic copyright has sometimes been seen as the Cinderella of copyright law. Simon Stokes argues that recent artistic copyright cases in Europe and North America are pushing copyright law to its limits. This has implications for the creative industries generally.

Jane Mutimear examines how the courts in Germany and the UK, as well as OHIM, have treated trade mark applications arising from generic domain names

Administrators of commercial companies in Colombia, whether national or foreign, must submit a report of performance to a general shareholders meeting. This must be done within the first three months of the fiscal year. Contained in the report must be a disclosure of the company's compliance with the provisions on IP and copyright.

Ralph Cunningham, Hong Kong

Pharmacia Corp, GD Searle & Co and Pfizer Inc (the patentees) were the proprietors of European Patent (UK) 0 679 157 (the patent) relating to chemical compounds having use as non-steroidal anti-inflammatory drugs (NSAIDs). The patentees appealed the findings at trial that the patent was invalid and not infringed by the defendants, Merck & Co Inc and Merck Sharp & Dohme Ltd (Merck). On appeal, the finding of invalidity was confirmed (Court of Appeal, December 14 2001). Merck's chemical compound, sold under the name Vioxx, was held to fall within claim 1 and would have infringed if the claim had not been held invalid.